KD-414 is a
COVID-19 vaccine candidate developed by
Japanesebiotechnology company KM Biologics Co.[1][2][3] Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.[4]
^Tanishima M, Ibaraki K, Kido K, Nakayama S, Ata K, Nakamura H, et al. (29 June 2022). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan".
medRxiv10.1101/2022.06.28.22276794.